In 2023, the United Kingdom led the European market for the production of blood and biological materials, valued at 560.4 million Euros, with a modest growth rate of 1.49%. Denmark followed with robust growth of 2.4%, accumulating 466.65 million Euros. Germany experienced a 5.16% growth, reaching 271.66 million Euros. Italy and France showed varied performances, with Italy growing by 1.75% and France contracting by 10.97%. The Netherlands and Austria had negative trends, while Hungary and Spain reported strong growth rates of 6.2% and 21.17%, respectively. Lithuania showed a positive growth trajectory with a 10.22% increase.
Future trends to watch include technological advancements in biologics production and increased demand for personalized medicine. Growth in Eastern European countries signals potential market shifts. Monitoring regulatory changes and investment in research and development will be crucial for maintaining competitiveness in the sector.
Top countries in Sold Production of Human Blood, Animal Blood Prepared for Therapeutic, Prophylactic or Diagnostic Uses, Cultures of Micro-Organisms, Toxins by Country
| # | 10 Countries | Euros | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 United Kingdom | 560,400,000 | 2023 | +2.32% | +1.49% | View data |
| 2 | 2 Denmark | 466,650,000 | 2023 | +2.89% | +2.4% | View data |
| 3 | 3 Germany | 271,660,000 | 2023 | +3.53% | +5.16% | View data |
| 4 | 4 Italy | 214,110,000 | 2023 | +5.31% | +1.75% | View data |
| 5 | 5 France | 131,080,000 | 2023 | -4.23% | -10.97% | View data |
| 6 | 6 Netherlands | 73,793,000 | 2023 | +2.4% | -4.22% | View data |
| 7 | 7 Austria | 38,376,000 | 2021 | View data | ||
| 8 | 8 Hungary | 30,763,000 | 2023 | +6.14% | +6.2% | View data |
| 9 | 9 Czechia | 23,145,000 | 2023 | |||
| 10 | 10 Spain | 22,082,000 | 2023 | +29.83% | +21.17% | View data |
